

**INVESTORS**

December 9th, 2024

Until now, our work has been essentially supported financially with non-dilutive financing from the Canadian Institutes of Health Research and private foundations.

Q4/2024 - Opportunities for investments and loans are **NOW available**. We are first currently seeking pre-seed funding ranging between $1,5 and $2,5M CAD (including dilutive and non-dilutive funds) as a bridge that will enable us to get operational, to obtain toxicology data, and to get prepared for the first large round (seed) of private equity financing.

Q3 or Q4/2025- We will soon begin **seeking** also to close a $10M CAD **seed round of private equity financing** to complete the preclinical development of our flagship product, TP-48, in order to launch the first-in-man trial in 2027 or sooner in overweight or obese but otherwise healthy subjects.